Novavax shifts to a partnership-focused strategy with a $500M Sanofi deal. Despite regulatory and competitive risks. See why ...

Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and Human Services Secretary ...

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay. The Secretary of Health and Human Services pointed to the ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

Peer-reviewed journals rejected their followup study on the 2023-2024 formulation of mRNA vaccines against the JN.1 variant ...

Dr. Peter Marks, an ex-FDA vaccine official, is warning of a fundamental change at the agency—where vaccine skepticism now ...

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novavax (NASDAQ: NASDAQ:NVAX) stock plummeted 24% after comments from Health and Human Services Secretary Robert F. Kennedy Jr. suggested a shift in government priorities away from the company’s ...

Robert F Kennedy Jr's controversial views on vaccines were on display this week during an interview with CBS News in which he ...

Shares of Novavax, Inc. (NVAX) plunged over 19.5% on Thursday after Health and Human Services Secretary Robert F. Kennedy Jr.

Just last week, the US Food and Drug Administration delayed a decision on full approval of Novavax’s Covid-19 vaccine even though it was on track to be cleared, leaving many public health ...